• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >CCN2: A novel, specific and valid target for anti-fibrotic drug intervention
【24h】

CCN2: A novel, specific and valid target for anti-fibrotic drug intervention

机译：CCN2：抗纤维化药物干预的新颖，特异性和有效靶点

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Prior attempts at developing anti-fibrotic therapies have focused on using growth factors and cytokines as targets. However, growth factors and cytokines have effects on normal physiology as well as fibrosis, making effective drug development difficult. Areas covered: Matricellular proteins alter the cellular microenvironment and hence cellular signaling responses to cytokines and growth factors. A survey of Pubmed reveals that the expression pattern of matricellular proteins notably that of CCN2 (connective tissue growth factor) is often altered in pathophysiological conditions such as fibrosis. Moreover, data presented in recent publications suggests that CCN2 directly mediates fibrosis. Expert opinion: As a result of these features, matricellular proteins such as CCN2, a member of the CCN family of matricellular proteins, might be ideal targets against which to develop novel therapeutic strategies.
机译：简介：先前开发抗纤维化疗法的尝试集中在使用生长因子和细胞因子作为靶标。然而，生长因子和细胞因子对正常的生理以及纤维化都有影响，使得有效的药物开发变得困难。覆盖区域：基质细胞蛋白改变细胞微环境，从而改变细胞对细胞因子和生长因子的信号响应。 Pubmed的一项调查显示，母体细胞蛋白的表达模式，特别是CCN2（结缔组织生长因子）的表达模式，在诸如纤维化的病理生理状况中经常发生变化。此外，最近出版物中提供的数据表明CCN2直接介导纤维化。专家意见：由于这些特性，诸如CCN2等基质细胞蛋白是基质细胞蛋白CCN家族的成员，可能是针对其开发新型治疗策略的理想靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号